Japan's mhlw approves padcev® (enfortumab vedotin) for advanced urothelial cancer

Tokyo & bothell, wash.--(business wire)--astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d., “astellas”) and seagen inc. (nasdaq:sgen) today announced that japan's ministry of health, labour and welfare (mhlw) has approved padcev® (enfortumab vedotin) for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. the new drug application received priority review. radically unresectable urothelial carcinoma is urothelial cancer that cann
SGEN Ratings Summary
SGEN Quant Ranking